An Epidemiological and Clinical Study of Monkeypox in Changsha, China: A Retrospective Analysis of HIV-Infected and Non-HIV-Infected Patients from June to December 2023
Jieqiong Li,Xuefeng Yuan,Jie Peng,Xingfang Hou,Fang Zheng,Gang Xiao,Xiaohui Liu
DOI: https://doi.org/10.2147/idr.s485232
2024-11-30
Infection and Drug Resistance
Abstract:Jieqiong Li, 1, &ast Xuefeng Yuan, 2, &ast Jie Peng, 3 Xingfang Hou, 4 Fang Zheng, 5 Gang Xiao, 5 Xiaohui Liu 6 1 Department of Pediatric, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, Hunan, People's Republic of China; 2 Department of Nosocomial Infection Management, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, Hunan, People's Republic of China; 3 Department of Neurosurgery, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, Hunan, People's Republic of China; 4 Department of Respiratory and Critical Care Medicine, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, Hunan, People's Republic of China; 5 Department of Infectious Diseases, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, Hunan, People's Republic of China; 6 Department of Pharmacy, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, Hunan, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiaohui Liu, Department of Pharmacy, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), 311 Yingpan Road, Changsha, Kaifu District, 410005, People's Republic of China, Tel +86 731 84667573, Fax +86 731 84667680, Email Background: The World Health Organization (WHO) declared Human Monkeypox (mpox) as a public health emergency of international concern (PHEIC) in July 2022. Due to border quarantine and isolation measures implemented from January 2020 to December 2022, Beijing did not report its first locally transmitted case of mpox until May 31, 2023, which represented a delayed occurrence compared to other countries. The aim of this observational analysis is to describe demographical data, symptoms presentation and clinical course till outcome of patients diagnosed with monkeypox (mpox) from June to December 2023 at a tertiary level hospital in Changsha, china. Patients and Methods: We conducted a retrospective study on 44 confirmed mpox cases and compared laboratory data between HIV-infected and non-HIV-infected patients at a tertiary general hospital in Changsha, China. Results: All patients were male, with a median age of 33 years. 88.6% patients had sex with men (MSM), and 88.9% HIV-infected patients accepted antiretroviral therapy (ART). The early symptoms of mpox typically include rashes and fever, which usually appear around the penis or anus. There were significant differences were found between HIV-infected and non-HIV-infected patients in laboratory data (P < 0.05), but none were clinically significant. Conclusion: This study underscores the importance of targeted mpox management strategies in MSM populations, particularly those co-infected with HIV and syphilis. Health authorities should consider proactive prevention and control measures, especially given the overlapping epidemics of HIV, syphilis, and mpox. Further studies are needed to explore the long-term clinical outcomes and potential benefits of vaccination in preventing mpox among high-risk populations. Keywords: Monkeypox virus, HIV, Syphilis, MSM, Rash Mpox, formerly known as human monkeypox, is a zoonotic disease caused by the mpox virus (MPXV), an enveloped, double-stranded DNA virus of the Orthopoxvirus genus of the Poxviridae family. 1 To date, three phylogenetically distinct clades of Monkeypox Virus (MPXV) have been identified. The "Central African" or "Congo Basin" clade is referred to as clade I, while the "West(ern) African" clade encompasses clades II and III. 2 The virus was first diagnosed in a 9-month-old boy from the Democratic Republic of the Congo (DRC) in 1970. 1 Clade II was responsible for the first outbreak of mpox outside Africa, which occurred in the United States in 2003. 1 In September 2017, another outbreak was identified in Nigeria. 1 Subsequently, on May 6, 2022, a United Kingdom national returning from Nigeria was diagnosed with mpox after developing a febrile rash. 1 This marked the beginning of the 2022 outbreak, which spread to non-endemic countries worldwide. 2–5 The World Health Organization (WHO) declared i -Abstract Truncated-
pharmacology & pharmacy,infectious diseases